Epicrispr Biotechnologies announced an oversubscribed $90 million Series C round to advance EPI-321, its lead epigenetic gene-silencing therapy for facioscapulohumeral muscular dystrophy. The funding is intended to move EPI-321 into pivotal trials, marking an important scale-up step from earlier clinical development. The company’s technology targets gene expression control without altering DNA, a strategy it has positioned as a potentially safer, reversible approach compared with permanent genome editing. Investors are betting on the clinical readiness of EPI-321 and the viability of the epigenetic mechanism. The financing also underscores ongoing investor willingness to fund platform-adjacent therapeutics when a clear clinical pathway is in view. If EPI-321 reaches pivotal milestones as planned, Epicrispr could accelerate toward a registrational readout that tests durability and functional impact in FSHD. As always in pivotal transitions, the near-term gating items are regulatory alignment on endpoints and manufacturing/CMC readiness to support late-stage trials at scale.